DrugNet: Network-based drug–disease prioritization by integrating heterogeneous data
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine
Zweig, M. H., & Campbell, G. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.561 · Cited by 6,569
Proceedings of the 25th international conference on Machine learning
Cohen, W. W., McCallum, A., & Roweis, S. T. (2008) · Cited by 5,691
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
An Information-Theoretic Definition of Similarity
Lin, D. (1998) · International Conference on Machine Learning · Cited by 4,776
Procedures for Detecting Outlying Observations in Samples
Grubbs, F. E. (1969) · Technometrics · doi:10.1080/00401706.1969.10490657 · Cited by 4,105 · cited 1×
“In order to help users focus on the most interesting cases, the tool marks statistically significant elements based on Grubbs’ test for outliers [60].”
MethodDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“While the cost of drug development is rising, the number of approved drugs has remained constant in recent years [2].”
BackgroundDrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812 · cited 1×
“Nevertheless, relations between biological entities are complex and mostly network-structured, and it is not yet clear which of the previous approaches is best, if any [25].”
BackgroundThe BioGRID interaction database: 2013 update
Chatr-aryamontri, A., Breitkreutz, B.-J., Heinicke, S., Boucher, L., Winter, A., Stark, C., Nixon, J., Ramage, L., Kolas, N., O’Donnell, L., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1158 · Cited by 1,017
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Disease Ontology: a backbone for disease semantic integration
Schriml, L. M., Arze, C., Nadendla, S., Chang, Y.-W. W., Mazaitis, M., Felix, V., Feng, G., & Kibbe, W. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr972 · Cited by 929
Methotrexate for the Treatment of Crohn's Disease
Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Gillies, R., Hopkins, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320503 · Cited by 911
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881 · cited 6×
“We performed a manual validation of interesting cases by comparing our results with those reported by PREDICT (Table S2 Supplementary Material)[20].”
MethodResultInfluentialPrediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference
Cheng, F., Liu, C., Jiang, J., Lu, W., Li, W., Liu, G., Zhou, W., Huang, J., & Tang, Y. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002503 · Cited by 818 · cited 2×
“This is also reflected in the wide range of network-based approaches existing in the drug repositioning field [7,9,10,27,28].”
BackgroundDiscovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816 · cited 1×
“Gene expression profiles are broadly used in this rea [8–12].”
MethodThe use of relative operating characteristic (ROC) curves in test performance evaluation.
Beck, & Shultz, E. K. (1986) · PubMed · Cited by 621
Drug–target interaction prediction by random walk on the heterogeneous network
Chen, X., Liu, M.-X., & Yan, G.-Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb00002d · Cited by 533 · cited 1×
“This is also reflected in the wide range of network-based approaches existing in the drug repositioning field [7, 9, 10, 27, 28].”
BackgroundExploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524 · cited 2×
“The development of a new drug is a risky process, lasting approximately 15 years and costing between $800 million and $1 billion [1].”
BackgroundThe Comparative Toxicogenomics Database: update 2013
Davis, A. P., Murphy, C. G., Johnson, R., Lay, J. M., Lennon-Hopkins, K., Saraceni-Richards, C., Sciaky, D., King, B. L., Rosenstein, M. C., Wiegers, T. C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks994 · Cited by 497
Shifting from the single to the multitarget paradigm in drug discovery
Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.008 · Cited by 483
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479 · cited 2×
“Since polypharmacological approaches aim to discover the unknown off-targets for existing drugs [15], computational drug repositioning is also applied to this area [16].”
BackgroundThe power of protein interaction networks for associating genes with diseases
Navlakha, S., & Kingsford, C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq076 · Cited by 358 · cited 2×
“The normalization previously described for M guarantees the convergence in this iterative process [32].”
MethodDonepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
Aarsland, D. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.708 · Cited by 341 · cited 1×
“It has recently been successfully used to treat Parkinson’s disease [45].”
MethodLevothyroxine Therapy in Patients with Thyroid Disease
Mandel, S. J., Brent, G. A., & Larsen, P. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-6-199309150-00009 · Cited by 324 · cited 1×
“In addition, other drugs suggested by DrugNet for treating myxedema are Levothyroxine [55] (ranked 1st), Desmopressin [56] (ranked 5th) and Vasopressin [57] (ranked 8th).”
BackgroundHuman Disease-Drug Network Based on Genomic Expression Profiles
Hu, G., & Agarwal, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006536 · Cited by 310 · cited 1×
“This is also reflected in the wide range of network-based approaches existing in the drug repositioning field [7, 9, 10, 27, 28].”
BackgroundSystematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses
Chiang, A. P., & Butte, A. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.103 · Cited by 268 · cited 1×
“[21] base their proposal on the ‘guilt-by-association’ (GBA) principle.”
BackgroundSystematic Drug Repositioning Based on Clinical Side-Effects
Yang, L., & Agarwal, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028025 · Cited by 266 · cited 1×
“For example, Promiscuous [18] and [19] relate diseases and drugs by considering drug side-effect information, since side effects are associated with certain symptomatology, which is sometimes shared with diseases.”
BackgroundDrug Target Prediction and Repositioning Using an Integrated Network-Based Approach
Emig, D., Ivliev, A., Pustovalova, O., Lancashire, L., Bureeva, S., Nikolsky, Y., & Bessarabova, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060618 · Cited by 241
Transcriptional data: a new gateway to drug repositioning?
Iorio, F., Rittman, T., Ge, H., Menden, M., & Saez-Rodriguez, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.014 · Cited by 237
Drug repositioning by structure-based virtual screening
Ma, D.-L., Chan, D. S.-H., & Leung, C.-H. (2013) · Chemical Society Reviews · doi:10.1039/c2cs35357a · Cited by 232
Drug repositioning for orphan diseases
Sardana, D., Zhu, C., Zhang, M., Gudivada, R. C., Yang, L., & Jegga, A. G. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr021 · Cited by 228 · cited 2×
“Finding new prescriptions for already commercialized drugs is a field known as drug repositioning [3].”
BackgroundPROMISCUOUS: a database for network-based drug-repositioning
von Eichborn, J., Murgueitio, M. S., Dunkel, M., Koerner, S., Bourne, P. E., & Preissner, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1037 · Cited by 225 · cited 1×
“For example, Promiscuous [18] and [19] relate diseases and drugs by considering drug side-effect information, since side effects are associated with certain symptomatology, which is sometimes shared with diseases.”
BackgroundXie, L., Xie, L., Kinnings, S. L., & Bourne, P. E. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134630 · Cited by 202 · cited 1×
“Therefore, new computational tools are required to analyze how multitarget drugs perturb target-disease networks on a proteome-wide scale [17].”
BackgroundThe role of vasopressin in the impaired water excretion of myxedema
Skowsky, W. R., & Kikuchi, T. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90581-8 · Cited by 197 · cited 1×
“In addition, other drugs suggested by DrugNet for treating myxedema are Levothyroxine [55] (ranked 1st), Desmopressin [56] (ranked 5th) and Vasopressin [57] (ranked 8th).”
BackgroundGuilt by Association: Contextual Information in Genome Analysis: Figure 1.
Aravind, L. (2000) · Genome Research · doi:10.1101/gr.10.8.1074 · Cited by 175
Microarrays--Guilt by Association
Quackenbush, J. (2003) · Science · doi:10.1126/science.1090887 · Cited by 164
Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
Fm, J. (1995) · PubMed · Cited by 158
Gabapentin as a Potential Treatment for Anxiety Disorders
Pollack, M. H., Matthews, J., & Scott, E. L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.992 · Cited by 158 · cited 1×
“Years of studies have shown that it is also useful in anxiety disorders [43].”
BackgroundColesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130 · cited 1×
“Further studies proved that colesevelam could be used in Type 2 diabetes mellitus to lower the rate of hypoglycemia [42].”
BackgroundMoreau, M., Rialland, P., Pelletier, J., Martel‐Pelletier, J., Lajeunesse, D., Boileau, C., Caron, J., Frank, D., Lussier, B., del Castillo, J. R. E., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3373 · Cited by 102
Computational Tools for Polypharmacology and Repurposing
Achenbach, J., Tiikkainen, P., Franke, L., & Proschak, E. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.62 · Cited by 77 · cited 1×
“Since polypharmacological approaches aim to discover the unknown off-targets for existing drugs [15], computational drug repositioning is also applied to this area [16].”
BackgroundThe disease and gene annotations (DGA): an annotation resource for human disease
Peng, K., Xu, W. M., Zheng, J., Huang, K., Wang, H., Tong, J., Lin, Z., Liu, J., Cheng, W., Fu, D., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1244 · Cited by 58
Díaz-Beltrán, L., Cano, C., Wall, D. P., & Esteban, F. J. (2013) · Behavioral Sciences · doi:10.3390/bs3020253 · Cited by 53 · cited 1×
“These relationships have proved critical for understanding the multifactorial nature of complex disorders [29].”
BackgroundSelf-citationThe year's new drugs & biologics - 2009
Graul, A. I., Sorbera, L., Pina, P., Tell, M., Cruces, E., Rosa, E., Stringer, M., Castaner, R., & Revel, L. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.1.1440373 · Cited by 48 · cited 1×
“Given these precedents, it is not surprising that in 2009, 30% of approved drugs were repositioned drugs for treating new indications [3,4].”
BackgroundProphNet: A generic prioritization method through propagation of information
Martínez, V., Cano, C., & Blanco, A. J. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-s1-s5 · Cited by 46 · cited 2×
“Page 7 of 42 Ac ce pt ed M an us cr ip t tion tool which has shown excellent results for gene-disease prioritization in our previous work [30].”
BackgroundMethodSelf-citationNetwork analysis has diverse roles in drug discovery
Hasan, S., Bonde, B. K., Buchan, N. S., & Hall, M. D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.006 · Cited by 43 · cited 1×
“Despite the number of different approaches, it seems clear that due to the network-shaped nature of biological information, graph-based approaches are well suited for extracting knowledge from existing biological data [26].”
BackgroundA Propagation-based Algorithm for Inferring Gene-Disease Assocations.
Vanunu, O., & Sharan, R. (2008) · German Conference on Bioinformatics · Cited by 35
Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases
Mei, H., Xia, T., Feng, G., Zhu, J., Lin, S. M., & Qiu, Y. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.06.015 · Cited by 30 · cited 2×
“The potential of disease pathways as a source of information for building disease networks is also promising [58].”
BackgroundMathur, S., & Dinakarpandian, D. (2011) · PubMed Central · Cited by 17
Effect of acute desmopressin and of long‐term thyroxine replacement on haemostasis in hypothyroidism
Erfurth, E. M., Ericsson, U. C., Egervall, K., & Lethagen, S. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02645.x · Cited by 16 · cited 1×
“In addition, other drugs suggested by DrugNet for treating myxedema are Levothyroxine [55] (ranked 1st), Desmopressin [56] (ranked 5th) and Vasopressin [57] (ranked 8th).”
BackgroundWalker, M. G., Volkmuth, W., & Klingler, T. M. (1999) · PubMed · Cited by 13
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“Thus, different AI-based algorithm and web-based tools have been developed in recent times such as DrugNet (http:// genom e2. ugr. es/ drugn et/) [274], DRIMC (https:// github. com/ linwa ng1982/ DRIMC) [275], DPDR-CPI (http:// cpi. bio-x. cn/ dpdr/) [276], PHARMGKB (https:// www. pharm gkb. org/)…”
MethodReview of Drug Repositioning Approaches and Resources
Xue, H., Li, J., Xie, H., & Wang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.24612 · Cited by 614
Building a knowledge graph to enable precision medicine
Chandak, P., Huang, K., & Zitnik, M. (2023) · Scientific Data · doi:10.1038/s41597-023-01960-3 · Cited by 522
Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm
Luo, H., Wang, J., Li, M., Luo, J., Peng, X., Wu, F.-X., & Pan, Y. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw228 · Cited by 477
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
Metadata
- Authors
- Martínez, V., Navarro, C., Cano, C., Fajardo, W., & Blanco, A.
- Venue
- Artificial Intelligence in Medicine
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 63
- Issue
- 1
- Pages
- 41-49
- ISSN
- 0933-3657 (ISSN-L)
- OpenAlex
- W2031954078
- Cited by
- 214
- References
- 51
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.